Category Archives: Stem Cell Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Leading stem cell therapeutic and regenerative medicine company, AuxoCell Laboratories, Inc., today announced an agreement with CordVida, a Brazilian stem cell cryopreservation company, which will allow CordVida to expand its services. Families who select CordVida to store umbilical cord blood will now have the opportunity to bank stem cells from an additional source cord tissue. With this agreement, AuxoCell broadens its international reach to South America. At AuxoCell, we are pleased by the opportunity to provide this groundbreaking technology to families around the globe, said Rouzbeh R. Taghizadeh, PhD, Chief Scientific Officer of AuxoCell Laboratories, Inc. CordVida is Brazils premier cord blood bank and adheres to the highest quality standards. It is for that reason that we have selected them as our exclusive partner in Brazil. Cord tissue has an abundant source of mesenchymal stem cells (MSCs). Currently, there is a significant amount of research underway focused on mesenchymal stem cells extracted from cord tissue. MSCs are rapidly becoming the leading stem cell in regenerative medicine studies, and MSCs from a variety of sources are in use in over 150 clinical trials. The AuxoCell cord tissue technology represents the gold standard in the industry, as its technology … Continue reading →

ALPHARETTA, Ga.--(BUSINESS WIRE)-- SANUWAVE Health, Inc. (SNWV), today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Companys Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone. In addition, the combination of ESWT-proliferated adult stem cells and a bioactive scaffold regenerated more bone than a bioactive scaffold alone. The publication, titled The Use of Extracorporeal Shock Wave-Stimulated Periosteal Cells for Orthotopic Bone Regeneration, appeared in the online edition of Tissue Engineering, Part A as an ePublication ahead of print. The abstract of the publication can be viewed online at: http://online.liebertpub.com/doi/abs/10.1089/ten.TEA.2011.0573. Led by Myron Spector, M.D., a professor and researcher at Harvard-MIT Division of Health Sciences and Technology, the authors stated, This study investigated a novel approach for treatment of bone loss, which has potential for many clinical situations where bone apposition is required (e.g., vertical ridge augmentation, regrowing bone following tumor resection, and regenerating bone lost at sites of osteolysis or bone degeneration). The cambium cells of the periosteum (outer membrane covering bone) currently have limited suitability for clinical applications in their native state due to their low cell number (only 2 to … Continue reading →

Stem Cell research at U of M may help patients with Lou Gehrigs disease. (File Photo) LANSING (WWJ) The University of Michigan would be required to report on its embryonic stem cell research program as part of the states new higher education budget. WWJ Lansing Bureau Chief Tim Skubick reports the Michigan Senate will vote this week on legislation that would order the University of Michigan to provide more data on its stem cell research. The House passed the legislation last week; the Senate is set to vote Tuesday. Its good news forMichigan Right to Life, which says it wants a closer look at what the university is doing. (What) They are doing is very controversial research some researchers get off into a corner and start doing things and if you are not making sure what it is they are up to then they can get off track just kind of a renegade, says Michigan Right To Life lobbyist Ed Rivet. Cynthia Wilbanks, a U-M vice president for government relations, told the Detroit Free Press the university has worked with lawmakers on the reporting requirement and believed it to be workable. Wilbanks added the report will include information that is … Continue reading →

Research scientist Dr Paul Turner (left) and cell biologist Dr Jim Faed examine bone marrow stem cell colonies in the Spinal Cord Society Research Laboratory in Dunedin. Photo by Gerard O'Brien. University of Otago cell biologist, haematologist and project leader Dr Jim Faed said $1.4 million was needed to trial the use of bone marrow stem cells to stimulate insulin production in type 1 diabetics. Fundraising is being co-ordinated by the Spinal Cord Society, which had started recruiting for a related trial for spinal cord injury sufferers, to be led by Dr Faed. That trial, which would have used cells from the person's nose, is on hold, partly for lack of funds, and partly because the diabetes trial would lay the groundwork for better-designed spinal cord research. The diabetes study would be carried out in the Spinal Cord Society Research Laboratory at Otago University's Centre for Innovation in Dunedin, taking about two years. Dr Faed said recent research from the United States had "electrified" interest in using stem cells to treat type 1 diabetics. In what is known as the Chicago study, umbilical cord stem cells were shown to increase insulin production in even the most severe diabetics. Dr Faed … Continue reading →

FARMINGTON, Conn., May 31, 2012 /PRNewswire-iReach/ -- BioInformant's two newest market researchs report offers mission-critical insight into the complex but lucrative world of embryonic stem cell product development and patent licensing. To promote these excellent products, Global Information Inc is offering our first 10 customers an Amazon Kindle Fire tablet with their purchase, as well as a copy of BioInformant's 2012 Marketing Database of Stem Cell Researchers, a combined $1500 value, absolutely free. (Photo: http://photos.prnewswire.com/prnh/20120531/CG15733) Error-Proof Entry, Expert Positioning, and Exploding Growth in Embryonic Stem Cell Products Companies interested in developing human embryonic stem cell products have to navigate a risky product environment. Due to the long-standing and controversial patents held by the University of Wisconsin's Alumni Research Foundation (WARF), companies have been largely hindered by the intellectual property (IP) environment restricting the development of embryonic stem cell products. However, going where competitors fear to tread means tremendous financial rewards are available for the companies that move boldly forward. Human embryonic stem cells offer tremendous therapeutic potential, as they can develop into over 200 different cell types. However, up until now, WARF has had the power to largely control what companies can develop embryonic stem cell products and on what … Continue reading →

Madison, Wisconsin - Breast-cancer researchers at the University of Wisconsin-Madison have found that two related receptors in a robust signaling pathway must work together as a team to maintain normal activity in mammary stem cells. Mammary stem cells produce various kinds of breast cell types. They may also drive the development and growth of malignant breast tumors. Published recently in the Journal of Biological Chemistry, the research also suggests that a new signaling pathway may be involved, a development that eventually could take cancer-drug manufacturers in a new direction. "We wanted to know if we could use this knowledge to inform us about what might be the transition that occurs to start tumor growth and maintain it," says senior author Dr. Caroline Alexander, professor of oncology at the McArdle Laboratory for Cancer Research at the School of Medicine and Public Health. The paper describes new information about the Wnt signaling pathway. Wnt signaling underlies numerous activities in normal development, but when the system is unregulated, cancer often occurs. More: Breast stem cell research: Receptor teamwork required and a new pathway may be involved … Continue reading →

Public release date: 30-May-2012 [ | E-mail | Share ] Contact: Dian Land dj.land@hosp.wisc.edu 608-261-1034 University of Wisconsin-Madison MADISON Breast-cancer researchers at the University of Wisconsin-Madison have found that two related receptors in a robust signaling pathway must work together as a team to maintain normal activity in mammary stem cells. Mammary stem cells produce various kinds of breast cell types. They may also drive the development and growth of malignant breast tumors. Published recently in the Journal of Biological Chemistry, the research also suggests that a new signaling pathway may be involved, a development that eventually could take cancer-drug manufacturers in a new direction. "We wanted to know if we could use this knowledge to inform us about what might be the transition that occurs to start tumor growth and maintain it," says senior author Dr. Caroline Alexander, professor of oncology at the McArdle Laboratory for Cancer Research at the School of Medicine and Public Health. The paper describes new information about the Wnt signaling pathway. Wnt signaling underlies numerous activities in normal development, but when the system is unregulated, cancer often occurs. "Wnt signaling is very important for both stem cells and tumor growth. We need to know … Continue reading →

LONDON, May 30,2012 /PRNewswire/ --Stem cell research is very dynamic with research trends, focus, and approaches evolving extremely rapidly. The tool market has to quickly adapt to these challenges and develop innovative tools that address and accelerate research accomplishments. New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), Strategic Analysis of the European Stem Cell Research Tools Market, finds that the market earned revenues of $148.4 million in 2011 and estimates this to reach $322.0 million in 2017. The segments covered include: bio-imaging and microscopy, cell biology tools, immunochemical, molecular biology tools, and protein biochemistry tools. "Firms with the capacity to supply tools for stem cell research will increase as the science matures," notes Frost & Sullivan Senior Research Analyst Divyaa Ravishankar. "Soon demand and supply will achieve a degree of equilibrium." Already, a sizeable stem cell research products market has emerged. Another positive sign for the market has been enhanced industry- academic collaboration. A key step forward has been the stem cell regulations in a few countries allowing the use of certain cell lines. In some countries such as France, for instance, stem cell regulations are being renewed for the procurement and use of stem cells. "Such trends indicate the potential … Continue reading →

Quotes are real-time for NASDAQ, NYSE, and NYSEAmex when available. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein. Fundamental company data provided by Capital IQ. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data and daily updates provided by Morningstar, Inc. Yahoo! - ABC News Network See the rest here: Biostem U.S., Corporation Appoints Philip A. Lowry, MD as Chairman of Its Scientific and Medical Board of Advisors … Continue reading →

Newswise TORONTO/HAMILTON (May 29, 2012) Actium Research Inc., (Actium or the Company) Toronto, and McMaster University (McMaster), Hamilton, have entered into a landmark collaboration covering McMasters proprietary adult human stem cell lines, cancer stem cells and the directed differentiation platform developed by Dr. Mick Bhatia and his team at the McMaster Stem Cell and Cancer Research Institute (The Stem Cell Institute). Together these technologies and the expertise at The Stem Cell Institute provide leading edge tools for drug discovery and better treatments for serious illnesses. Actium is a drug discovery and development company targeting two types of stem cells; cancer stem cells to improve survival and health outcomes and normal tissue stem cells to promote healing and address the need for cure in chronic diseases. Actium was founded by Dr. David Young and Helen Findlay. Dr. Bhatia joined as the scientific founder in 2012. The team will put their experience with managing drug discovery platforms, development pathways and product pipelines to work to build Actium into a leading biotech company. Previously, Dr. David Young and Ms Helen Findlay were uniquely successful in creating ARIUS Research Inc. (ARIUS), a public biotech company, trading on the TSX, specializing in the discovery and … Continue reading →